Global Varicella Vaccine Market Size

Varicella Vaccine Market Analysis

The varicella vaccine market is expected to register a CAGR of 5.6% during the forecast period, 2022-2027.

The acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease has been linked to T-cell immunological dysfunction. Herpes zoster reactivation could be brought on by COVID-19 infection. According to the study titled "Can, COVID-19 Increase the Risk of Herpes Zoster? A Narrative Review" published in the Dermatology and therapy in August 2021, Varicella-zoster virus reactivation on COVID-19 patients can be brought on by T cell dysfunction, such as lymphopenia and lymphocyte depletion. Due to COVID-19's propensity to develop an immunosuppressive state, which is linked to the functional impairment and concurrent quantitative decline in T lymphocytes, particularly CD4+ T cells, CD8+ T cells, and natural killer cells, patients with COVID-19 are more likely to experience reactivation of herpes zoster. Moreover, according to the study titled "Herpes zoster in the era of COVID 19: A prospective observational study to probe the association of herpes zoster with COVID 19 infection and vaccination" published in the National Library of Medicine in June 2022, reported that during post-marketing surveillance, reactivation of the varicella-zoster virus has occasionally been reported following vaccination for SARS-CoV-2. Therefore, during the ongoing COVID-19 outbreak, managing varicella infection has become more crucial.

The market is driven by the rising prevalence of the target diseases, growing awareness regarding the use of the varicella vaccine, and an increase in immunization programs across the world. For Instance, In August 2020, GSK reported the launch of DT campaign for shingrix vaccine targeted against the aging for vaccination against vericella. Similatly, as per the National Health Mission in July 2022, One of the biggest public health initiatives, the Universal Immunization Program (UIP), targets nearly 2.67 billion newborns and 2.9 billion expectant mothers each year against diseases including measles, rubella, chickenpox, and other. Thus, a growing immunization program against the varicella zoster is expected to drive the demand for varicella vaccines thereby boosting the market growth.

However, the growing prevalence of varicella or chickenpox is anticipated to drive the growth of the market. For instance, according to the study titled "Epidemiological analysis of varicella in Dalian from 2009 to 2019 and application of three kinds of the model in prediction prevalence of varicella' published in the BMC Public Health in April 2022, the prevalence was 50.56/100000 on a yearly average. The bimodal distribution of varicella was constant throughout the year. Moreover, according to the Center for Diseases Control and Prevention in May 2021, Herpes zoster affects people 60 and older at a rate of about 1 case per 100 in the U.S. each year, and 1 to 4% of patients end up in hospitals for complications, 30% of whom have weakened immune systems. Elderly people are more prone to herpes zoster due to weakened immune systems. However, the high cost of vaccines restraint the market growth.

Furthermore, growing awareness regarding varicella vaccine usage, active participation of the government in immunization programs, and a surge in the acceptance of varicella vaccines are the key driving factors in the varicella vaccine market. However, high cost of the vaccine restraint the market growth.